These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 27048170)

  • 1. Safety and tolerability of BAN2401--a clinical study in Alzheimer's disease with a protofibril selective Aβ antibody.
    Logovinsky V; Satlin A; Lai R; Swanson C; Kaplow J; Osswald G; Basun H; Lannfelt L
    Alzheimers Res Ther; 2016 Apr; 8(1):14. PubMed ID: 27048170
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.
    Swanson CJ; Zhang Y; Dhadda S; Wang J; Kaplow J; Lai RYK; Lannfelt L; Bradley H; Rabe M; Koyama A; Reyderman L; Berry DA; Berry S; Gordon R; Kramer LD; Cummings JL
    Alzheimers Res Ther; 2021 Apr; 13(1):80. PubMed ID: 33865446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The murine version of BAN2401 (mAb158) selectively reduces amyloid-β protofibrils in brain and cerebrospinal fluid of tg-ArcSwe mice.
    Tucker S; Möller C; Tegerstedt K; Lord A; Laudon H; Sjödahl J; Söderberg L; Spens E; Sahlin C; Waara ER; Satlin A; Gellerfors P; Osswald G; Lannfelt L
    J Alzheimers Dis; 2015; 43(2):575-88. PubMed ID: 25096615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-In-Human safety and long-term exposure data for AAB-003 (PF-05236812) and biomarkers after intravenous infusions of escalating doses in patients with mild to moderate Alzheimer's disease.
    Delnomdedieu M; Duvvuri S; Li DJ; Atassi N; Lu M; Brashear HR; Liu E; Ness S; Kupiec JW
    Alzheimers Res Ther; 2016 Mar; 8(1):12. PubMed ID: 26925577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamic effect of crenezumab on plasma and cerebrospinal fluid beta-amyloid in patients with mild-to-moderate Alzheimer's disease.
    Yoshida K; Moein A; Bittner T; Ostrowitzki S; Lin H; Honigberg L; Jin JY; Quartino A
    Alzheimers Res Ther; 2020 Jan; 12(1):16. PubMed ID: 31969177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, Tolerability, and Pharmacokinetics of Crenezumab in Patients with Mild-to-Moderate Alzheimer's Disease Treated with Escalating Doses for up to 133 Weeks.
    Guthrie H; Honig LS; Lin H; Sink KM; Blondeau K; Quartino A; Dolton M; Carrasco-Triguero M; Lian Q; Bittner T; Clayton D; Smith J; Ostrowitzki S
    J Alzheimers Dis; 2020; 76(3):967-979. PubMed ID: 32568196
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
    Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
    Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Updated safety results from phase 3 lecanemab study in early Alzheimer's disease.
    Honig LS; Sabbagh MN; van Dyck CH; Sperling RA; Hersch S; Matta A; Giorgi L; Gee M; Kanekiyo M; Li D; Purcell D; Dhadda S; Irizarry M; Kramer L
    Alzheimers Res Ther; 2024 May; 16(1):105. PubMed ID: 38730496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.
    Andreasen N; Simeoni M; Ostlund H; Lisjo PI; Fladby T; Loercher AE; Byrne GJ; Murray F; Scott-Stevens PT; Wallin A; Zhang YY; Bronge LH; Zetterberg H; Nordberg AK; Yeo AJ; Khan SA; Hilpert J; Mistry PC
    PLoS One; 2015; 10(3):e0098153. PubMed ID: 25789616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SAR228810: an antibody for protofibrillar amyloid β peptide designed to reduce the risk of amyloid-related imaging abnormalities (ARIA).
    Pradier L; Blanchard-Brégeon V; Bohme A; Debeir T; Menager J; Benoit P; Barneoud P; Taupin V; Bertrand P; Dugay P; Cameron B; Shi Y; Naimi S; Duchesne M; Gagnaire M; Weeden T; Travaline T; Reczek D; Khiroug L; Slaoui M; Brunel P; Fukuyama H; Ravetch J; Canton T; Cohen C
    Alzheimers Res Ther; 2018 Nov; 10(1):117. PubMed ID: 30486882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas RG; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    Alzheimers Res Ther; 2024 Jul; 16(1):151. PubMed ID: 38970127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease.
    Cantillon M; Andreasen N; Prins N
    J Prev Alzheimers Dis; 2024; 11(1):65-70. PubMed ID: 38230718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Japanese Subgroup Analyses from EMERGE and ENGAGE, Phase 3 Clinical Trials of Aducanumab in Patients with Early Alzheimer's Disease.
    Toda Y; Iwatsubo T; Nakamura Y; Matsuda N; Miyata M; Jin M; Chen T; Kuribayashi K; Tian Y; Hughes R; Yamamoto J; Muralidharan KK; Rubel C; Hutchison RM; Budd Haeberlein S
    J Prev Alzheimers Dis; 2024; 11(5):1260-1269. PubMed ID: 39350371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Safety, Pharmacokinetics, and Biomarker Results of Subcutaneous Bapineuzumab in Patients with mild to moderate Alzheimer's disease.
    Brody M; Liu E; Di J; Lu M; Margolin RA; Werth JL; Booth K; Shadman A; Brashear HR; Novak G
    J Alzheimers Dis; 2016 Oct; 54(4):1509-1519. PubMed ID: 27589523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study.
    Landen JW; Zhao Q; Cohen S; Borrie M; Woodward M; Billing CB; Bales K; Alvey C; McCush F; Yang J; Kupiec JW; Bednar MM
    Clin Neuropharmacol; 2013; 36(1):14-23. PubMed ID: 23334070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and biomarker effects of solanezumab in patients with Alzheimer's disease.
    Farlow M; Arnold SE; van Dyck CH; Aisen PS; Snider BJ; Porsteinsson AP; Friedrich S; Dean RA; Gonzales C; Sethuraman G; DeMattos RB; Mohs R; Paul SM; Siemers ER
    Alzheimers Dement; 2012 Jul; 8(4):261-71. PubMed ID: 22672770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, tolerability and immunogenicity of an active anti-Aβ
    Lacosta AM; Pascual-Lucas M; Pesini P; Casabona D; Pérez-Grijalba V; Marcos-Campos I; Sarasa L; Canudas J; Badi H; Monleón I; San-José I; Munuera J; Rodríguez-Gómez O; Abdelnour C; Lafuente A; Buendía M; Boada M; Tárraga L; Ruiz A; Sarasa M
    Alzheimers Res Ther; 2018 Jan; 10(1):12. PubMed ID: 29378651
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease.
    Uenaka K; Nakano M; Willis BA; Friedrich S; Ferguson-Sells L; Dean RA; Ieiri I; Siemers ER
    Clin Neuropharmacol; 2012; 35(1):25-9. PubMed ID: 22134132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.